Leading player in the branded and generic formulations and API space, Lupin launched an emergency kit for the treatment of severe low blood sugar in the US, a company statement said on August 11.
The drug category has an estimated annual sale of $122 million in the US, according to IQVIA data. Shares of Lupin were marginally higher in the session, sharply rising after the announcement was made public.
Lupin's 'Glucagon for Injection USP' (1mg/vial), packaged in an emergency kit, is a bioequivalent to Eli Lilly's injection.
Glucagon is recommended for the treatment of severe hypoglycemia in children as well as adult patients suffering from diabetes. It is also a diagnostic aid in gastrointestinal imaging during radiologic examinations of adult patients.
Lupin has been attempting to establish injectables and biosimilars as a growth driver, leveraging on its capabilities both in R&D and manufacturing. "...this year in particular, we're going to see a material inflection on the injectables front with products like Glucagon, Liraglutide, Risperdal Consta coming to market," Lupin said in May 2025.
The USFDA has been easing regulations around emerging biologics as well as the private label business, shaping up biosimilars as a growth driver going ahead. The launch is part of Lupin's injectables pipeline, with as many as 30 products in the pipeline, along with biosimilars and inhalations.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
